Literature DB >> 33704742

Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.

Mohammad A Obeid1, Alaa A A Aljabali2, Meriem Rezigue2, Haneen Amawi3, Hanin Alyamani4, Shatha N Abdeljaber2, Valerie A Ferro4.   

Abstract

Melanoma accounts for 4% of all skin cancer malignancies, with only 14% of diagnosed patients surviving for more than 5 years after diagnosis. Until now, there is no clear understanding of the detailed molecular contributors of melanoma pathogenesis. Accordingly, more research is needed to understand melanoma development and prognosis.All the treatment approaches that are currently applied have several significant limitations that prevent effective use in melanoma. One major limitation in the treatment of cancer is the acquisition of multidrug resistance (MDR). The MDR results in significant treatment failure and poor clinical outcomes in several cancers, including skin cancer. Treatment of melanoma is especially retarded by MDR. Despite the current advances in targeted and immune-mediated therapy, treatment arms of melanoma are severely limited and stand as a significant clinical challenge. Further, the poor pharmacokinetic profile of currently used chemotherapeutic agents is another reason for treatment failure. Therefore, more research is needed to develop novel drugs and carrier tools for more effective and targeted treatment.Nucleic acid therapy is based on nucleic acids or chemical compounds that are closely related, such as antisense oligonucleotides, aptamers, and small-interfering RNAs that are usually used in situations when a specific gene implicated in a disorder is deemed a therapeutically beneficial target for inhibition. However, the proper application for nucleic acid therapies is hampered by the development of an effective delivery system that can maintain their stability in the systemic circulation and enhance their uptake by the target cells. In this chapter, the prognosis of the different types of melanoma along with the currently used medications is highlighted, and the different types of nucleic acids along with the currently available nanoparticle systems for delivering these nucleic acids into melanoma cells are discussed. We also discuss recently conducted research on the use of different types of nanoparticles for nucleic acid delivery into melanoma cells and highlight the most significant outcomes.

Entities:  

Keywords:  Drug delivery; Melanoma; Multidrug resistance; Nanoparticles; Nucleic acids

Mesh:

Substances:

Year:  2021        PMID: 33704742     DOI: 10.1007/978-1-0716-1205-7_41

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  140 in total

1.  CDKN2A variants in a population-based sample of Queensland families with melanoma.

Authors:  J Aitken; J Welch; D Duffy; A Milligan; A Green; N Martin; N Hayward
Journal:  J Natl Cancer Inst       Date:  1999-03-03       Impact factor: 13.506

2.  Later stage at diagnosis and worse survival in cutaneous malignant melanoma among men living alone: a nationwide population-based study from Sweden.

Authors:  Hanna Eriksson; Johan Lyth; Eva Månsson-Brahme; Margareta Frohm-Nilsson; Christian Ingvar; Christer Lindholm; Peter Naredi; Ulrika Stierner; John Carstensen; Johan Hansson
Journal:  J Clin Oncol       Date:  2014-03-31       Impact factor: 44.544

Review 3.  Melanoma.

Authors:  Arlo J Miller; Martin C Mihm
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 4.  [Synchronous multiple primary melanoma are often missed. Increased attention to the patient's entire skin is required for early diagnosis].

Authors:  Jan Lapins; Lennart Emtestam; Mari-Anne Hedblad; Ada Girnita; Bernt Lindelöf; Anders Ljung; Johan Hansson
Journal:  Lakartidningen       Date:  2013 Feb 20-26

Review 5.  The role of radiation therapy in the management of cutaneous melanoma.

Authors:  Nikhil G Rao; Hsiang-Hsuan M Yu; Andrea Trotti; Vernon K Sondak
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

Review 6.  Ultraviolet radiation and skin cancer.

Authors:  Deevya L Narayanan; Rao N Saladi; Joshua L Fox
Journal:  Int J Dermatol       Date:  2010-09       Impact factor: 2.736

7.  Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color.

Authors:  C Kennedy; J ter Huurne; M Berkhout; N Gruis; M Bastiaens; W Bergman; R Willemze; J N Bavinck
Journal:  J Invest Dermatol       Date:  2001-08       Impact factor: 8.551

Review 8.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 9.  Chemoprevention of melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Systematic review of medical treatment in melanoma: current status and future prospects.

Authors:  Claus Garbe; Thomas K Eigentler; Ulrich Keilholz; Axel Hauschild; John M Kirkwood
Journal:  Oncologist       Date:  2011-01-06
View more
  2 in total

Review 1.  SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.

Authors:  Adedapo Adesokan; Mohammad A Obeid; Aisha F Lawal
Journal:  Ther Deliv       Date:  2022-02-23

Review 2.  New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.

Authors:  Adelina-Gabriela Niculescu; Alexandra Cătălina Bîrcă; Alexandru Mihai Grumezescu
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.